Back to search

Peptide record

TPDB92500

IDP-LS17 Anticancer standard
16 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92500
IDP-LS17
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 16-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Chemical: -(CH2)6-CH=CH-(CH2)3 Chemical: a biradical linker links S(8) and Q(15)
Sequence
APKVVILSKALEYLQA
Physicochemical Analysis
C82H139N19O22
RNDCGHMFTW
AL
1743.12
9.65
2
1
10
+1
1.86
0.700
152.50
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
1490
85.48
3
Residue Composition
number
3
A
0
R
0
N
0
D
0
C
1
E
1
Q
0
G
0
H
1
I
3
L
2
K
0
M
0
F
1
P
1
S
0
T
0
W
1
Y
2
V
Amino Acid Distribution
A: 3 R: 0 N: 0 D: 0 C: 0 E: 1 Q: 1 G: 0 H: 0 I: 1 L: 3 K: 2 M: 0 F: 0 P: 1 S: 1 T: 0 W: 0 Y: 1 V: 2
Chemical Descriptors
16
C82H139N19O22
1743.12
9.65
+1
1.86
0.700
Free
-(CH2)6-CH=CH-(CH2)3 a biradical linker links S(8) and Q(15)
L
Linear
Free
Anticancer
Synthetic
Evidence Records 2 records
Evidence 1 Activity

Activity

EC50
EC50 ~ 10 µM
Anticancer
10 µM

Target

Leukemia Cancer
RPMI
Blood

Assay & Model

MTT/Alamamar-Blue/Hexosaminidase activity test
48-72 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200239547A1

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

EC50
EC50 ~ 16 µM
Anticancer
16 µM

Target

Lymphoma Cancer
U266
Blood

Assay & Model

MTT/Alamamar-Blue/Hexosaminidase activity test
48-72 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
US20200239547A1